---
title: "上海仁度生物科技股份有限公司 (688193.SH)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/688193.SH.md"
symbol: "688193.SH"
name: "上海仁度生物科技股份有限公司"
industry: "医疗用品"
---

# 上海仁度生物科技股份有限公司 (688193.SH)

| Item | Detail |
|------|--------|
| Industry | 医疗用品 |
| Location | 沪深市场 |
| Website | [www.rdbio.com](https://www.rdbio.com) |

## Company Profile

公司专注于 RNA 分子诊断技术和产品研发、生产和销售的创新型企业。自创立以来，公司一直致力于研发、推广以 RNA 实时荧光恒温扩增检测 (SAT) 技术平台为基础的 RNA 分子诊断试剂和配套自动化设备。公司主要业务为研发、生产和销售以 SAT 技术平台为基础的分子诊断试剂和设备，专注于为生殖、呼吸、消化、血源等领域病原体的精准诊断、有效防控和个性化诊疗提供解决方案。公司主要产品：生殖道 (沙眼衣原体、淋病奈瑟菌、解脲脲原体、生殖支原体)、呼吸道 (结核分枝杆菌、肺炎支原体) 和血源传染病等系列核酸检测试剂产品、核酸提纯仪、全自动核酸提取仪 (NAPure96)、全自动核酸检测分析系统 (A...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-16T04:30:09.000Z

**Overall: C (0.60)**

**Industry**: Health Care Supplies

| Metric | Value |
|--------|-------|
| Industry Ranking | 35 / 41 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -6.80% |  |
| Net Profit YoY | -125.71% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 2.35 |  |
| Dividend Ratio | 0.45% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2.14B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 165.87M |  |


**Multi Score**: C

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -0.59% | D |
| Profit Margin | -3.30% | D |
| Gross Margin | 79.09% | A |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -6.80% | D |
| Net Profit YoY | -125.71% | E |
| Total Assets YoY | -1.50% | D |
| Net Assets YoY | -0.96% | D |

#### Cash Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -3032.41% | E |
| OCF YoY | -6.80% | D |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.17 | D |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 7.25% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 上海仁度生物科技股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-0.59%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-3.30%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "79.09%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-6.80%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-125.71%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-1.50%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-0.96%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "E",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-3032.41%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "-6.80%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.17",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "7.25%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 新产业 (SZ.300832) | A | C | C | A | C | B |
| 02 | 稳健医疗 (SZ.300888) | B | A | B | B | B | B |
| 03 | 南微医学 (SH.688029) | A | B | B | A | B | B |
| 04 | 爱博医疗 (SH.688050) | A | B | C | B | C | B |
| 05 | 圣湘生物 (SH.688289) | B | B | D | B | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -391.79 | 40/41 | 73.71 | 71.47 | 67.80 |
| PB | 2.35 | 20/41 | 2.27 | 2.07 | 1.68 |
| PS (TTM) | 12.92 | 35/41 | 12.24 | 11.00 | 8.81 |
| Dividend Yield | 0.45% | 32/41 | 0.76% | 0.48% | 0.39% |

## References

- [Company Overview](https://longbridge.com/en/quote/688193.SH/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/688193.SH/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/688193.SH/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.